Abstract
INTRODUCTION
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths. The prognosis of CRC is dependent upon the extent of disease and approximately 60% of patients develop metastases after surgical resection. With a 5-year survival rate of less than 10% in patients with distant metastatic disease, targeting the metastatic process and sites should provide an effective treatment [1] . The progressive growth of colon cancer and subsequent metastatic process is dependent on an angiogenic network [2, 3] . Thus, anti-angiogenic strategies have emerged as effective therapies in patients with colon cancer, especially in the metastatic setting of the disease [4] [5] [6] . Yet, differences in the magnitude of survival benefit point to alternative pathways in the tumor microenvironment as responsible for inconsistent outcomes [7] . Angiogenesis is a complex process dependent on the angiogenic factors secreted by the tumor and stroma cells [8] . Vascular endothelial growth factor is considered the major pro-angiogenic factor [9] . The vascular endothelial growth factor (VEGF) gene encodes for six alternatively spliced isoforms [10] with differential diffusion potential and binding to receptors [11] . The question currently consists of understanding the significance of VEGF/vascular endothelial growth factor receptor (VEGFR) signaling in cancer cells [12, 13] . The VEGF isoforms and VEGF receptor expression pattern would drive the activity and functionality of the VEGF/VEGFR pathway in both tumor and endothelial cells. The multistep process of angiogenesis accompanies the multistage development of a tumor [14] . The switch into the metastatic phenotype brings a number of changes within the tumor microenvironment, including acquisition of hypoxia-tolerance mechanisms [15] . While up-regulation of VEGF expression is activated mainly under hypoxia [9] , recent reports reflect on the question of whether metastatic tumors rely as much on angiogenesis and VEGF as primary tumors [15] . Other studies report that tumors in more advanced stages do not rely on a unique angiogenesis driver [2] . A network of multiple cytokines and growth factors create a crosstalk within the tumor microenvironment which ultimately drives tumor angiogenesis [2, 16] . The mediators of vessel wall remodeling matrix metalloproteinases, macrophage chemoattractant proteins and angiopoietin, involved in invasion and metastasis processes, exert proangiogenic signals [8, 17] . Chemokines such as interleukin (IL)-1α and IL-8 play an important role in colon cancer progression and angiogenesis [18] , and IL-8 up-regulates MMPs [19] . VEGF expression actually determines the activity of Ang-1/Ang-2 and the expression of MCPs [20, 21] . Great efforts have been made to characterize biomarkers in CRC [22] . However, the question of biomarkers of CRC metastasis remains currently unresolved. On this basis, the aim of this study was to characterize the protein factors behind the angiogenic potential of CRC cell lines of metastatic origin.
MATERIALS AND METHODS

Cell cultures and conditioned media
We used 16 CRC cell lines: HT29, WiDr, HCT116, RKO, SW480, Colo320, Caco2, SW1116, LS174T, SW1417, DLD-1, LS513, HCT15, SW620, LoVo and T84 (all from American Type Culture Collection, Manassas, VA) ( Table 1 ). The cell lines were maintained in the recommended growth media supplemented with 10% fetal bovine serum (GIBCO) and 1% penicillin/streptomycin (GIBCO). For harvesting conditioned media, CRC lines cells were grown approximately to 70% confluence in serum free media. The conditioned media were collected after 24 h of incubation, centrifuged and kept frozen. Total VEGF and isoforms mRNA determination by quantitative reverse-transcription polymerase chain reaction Total RNA was isolated using the RNeasy kit (Qiagen, Valencia, CA). Single strand DNA was synthesized from 1 μg total RNA using the cDNA Archive kit (Applied Biosystems). Quantitative reverse-transcription polymerase chain reaction (Q-RT-PCR) for total VEGF was performed using primers and probes purchased from Applied Biosystems (Hs00900054_m1). RNA18s (Hs99999901_s1) was used as an endogenous control and data obtained was represented as 2-∆Ct. VEGF isoforms were determined by Q-RT-PCR using primers designed specifically for VEGF121, VEGF165, and VEGF189, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an endogenous control ( Table 2 ). The relative quantification of samples was performed using a standard curve by dilution of a specific plasmid for each isoform (ranging from 10 pg to 1 fg). Human VEGF cDNA for each isoform and GAPDH were cloned from total RNA isolated from lung cancer resection as follows. PCR products were run through a 1% agar gel and bands of the size expected for VEGF121, VEGF165 and VEGF189 were isolated and purified. Each VEGF isoform was cloned into the pCRII vector (Invitrogen) and sequenced (ABI PRISM Big Dye Terminator Cycle Sequencing reaction kit; ABI Protocol, Gene Amp 9600, Applied Biosystems) to verify its identity.
VEGF
Time course hypoxia-normoxia
The cell lines were maintained in the recommended growth media supplemented with 10% fetal bovine serum (GIBCO) and 1% penicillin/streptomycin (GIBCO). After washing with phosphate buffered saline (PBS), serum-free medium was added and the cells exposed to normoxic or hypoxic conditions for 6 h, 12 h, 24 h, 36 h, 48 h and 72 h. Hypoxic conditions were achieved by culturing cells in a modulator incubation chamber (Sanyo MCO-18 M) gassed with 1% O2, 50 mL/L CO2, and 94% N2. VEGF protein secretion was measured in the supernatant by enzyme immune-assay (EIA) and VEGF mRNA levels by Q-RT-PCR. Cell proliferation was evaluated by the Trypan Blue exclusion method.
VEGFR-2 expression in colorectal cancer cell lines by flow cytometry
The expression of VEGFR-2 (KDR) in CRC cell lines was determined by flow cytometry (FacScan, BectonDickinson). After trypsinization, cells were incubated in medium for 12 h on a rocker platform to enable regeneration of the receptors. Cells were Fc-blocked by treatment with 100 μL of AB human serum for 15 min at room temperature prior to staining with 10 μL of PEconjugated anti-VEGFR-2 antibody (Becton Dickinson Biosystems) for 30 min at 4 ℃. Following the incubation, unbounded anti-VEGFR-2 antibody was removed by washing the cells twice in 4 mL PBS buffer. The human umbilical vein endothelial cells (HUVEC) cell line was used as a positive control.
Secreted angiogenic profile by cytokine antibody-array
The secretion of angiogenic factors by CRC cell lines was evaluated in duplicate using a protein array method (RayBio ® Human Angiogenesis Antibody Array, RayBiotech C Series 1000, RayBiotech, Inc Norgross, GA). This assay is capable of simultaneously detecting 44 different angiogenic factors (spotted in sub-arrays Ⅰ and Ⅱ) with high specificity. The sensitivity of the antibodies present in the arrays ranged from 1-2000 pg/mL. Conditioned media was obtained after the incubation of 2 × 10 5 cells in serum-free medium for 20 h at 37 ℃ and 5% CO2. Each array was incubated with 1.2 mL of medium at 4 ℃ overnight, and bound antigens were detected according to the manufacturer's instructions. To determine the relative concentrations of angiogenic factors in the media, the densities of individual spots were measured using Imagene 4.1 software (Biodiscovery Inc., Marina Del Rey, United States) for image capture and analysis.
Statistical analysis
Statistical analysis was carried out with SPSS 13.0 soft- 
RESULTS
Distinct angiogenesis-related expression pattern in primary and metastatic colorectal cancer cell lines
To identify the angiogenesis-related "secretome" of CRC cell lines in normoxia, we analyzed 44 angiogenesisrelated cytokines and growth factors by an antibody-array in primary (Caco2, SW1417, DLD1, HT29 and SW480) and metastatic (SW620 and T84) CRC cell lines. K-means analysis classified CRC cell line angiogenesis-related secreted factors according to their level of secretion ( Figure  1A ). Cluster Ⅰ showed a homogeneous high expression of the pro-angiogenic IL-8, MMP-1, MCP-1, growth related oncogene (GRO)-α, regulated upon activation, ware (SPSS Inc.). Associations between VEGF expression and VEGF isoforms pattern were determined with the Spearman correlation. Differences between groups were determined by the Mann-Whitney U test. The level of two-tailed statistical significance was 0.05. CRC cell line angiogenesis cytokine antibody-arrays raw data were normalized to the global median [BRB Array Tools 3.6.0 (NCI)] of signals detected as per manufacturer's instructions. GENESIS software (Institute for biomedical engineering, Graz University of Technology, Graz, Austria) was used for the analyses of clustering of samples and genes and K-means and hierarchical unsupervised clustering analyses were performed to determine cytokine profiles.
Cluster 1-9 genes
Cluster 3-11 genes Cluster 2-9 genes Cluster 4-10 genes Figure 1A , cluster Ⅰ). Cluster Ⅱ integrated angiogenic factors not secreted by CRC cell lines in normoxia, including VEGF family proteins placental growth factor (PlGF) and sVEGFR-2 and inflammatory cytokines with pro-angiogenic properties granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), IFN-γ, tumor necrosis factor-α (TNF-α) ( Figure 1A , cluster Ⅱ).
Primary tumor-and metastasis-derived CRC cell lines were characterized by a distinct angiogenesis-related molecular pattern in normoxia ( Figure 1A , cluster Ⅲ and Ⅳ). Figure 1B shows the unsupervised hierarchical clustering of the antibody-array proteins significantly differing in expression according to their cellular origin. One-way ANOVA (P < 0.05) grouped primary and metastatic cell lines according to their differential molecular expression pattern. Metastasis-derived cell lines were characterized by higher expression of Ang-2, MCP-3, MCP-4, MMP-1 and the chemokines I-TAC, I-309, IL-2 and IL-1α (P < 0.05), and a trend was found for MMP-9, as compared to primary tumor cell lines ( Figure 1B ). On the other hand, CRC cell lines isolated from a primary tumor site were clustered together according to the higher expression of IFN-γ, IGF-1, IL-6, leptin, EGF, PlGF, thrombopoietin, TGF-β1 and VEGF-D (P < 0.05), as compared with the metastatic ones ( Figure 1B ). Interestingly, VEGF-A (VEGF) was not found among the proteins differentially expressed according to the cellular source of isolation. Figure 1C illustrates processed antibody-arrays and the images captured of Caco2 (primary CRC cell line) and T84 (metastatic CRC cell line).
VEGF expression in primary and metastatic colorectal cancer cell lines
The antibody array data showed no significant changes in VEGF secretion between primary and metastasis-derived CRC cell lines ( Figure 1B) . To validate the antibody array results, we analyzed VEGF levels by EIA. The results were confirmed by a statistically significant positive correlation between VEGF protein as determined by the antibody-array and by EIA (r Spearman = 0.7, P < 0.05) (Figure 2A) . In a second step, VEGF secretion by EIA and VEGF mRNA expression was analyzed in a larger panel of 16 CRC cell lines. As shown in Figure 2B and C, we did not detect any significant difference in VEGF expression according to the primary or metastatic CRC cell lines (mean of 28.9 pg/mL and 22.7 pg/mL VEGF protein; 0.011 and 0.009 (relative quantification) VEGF mRNA, respectively). Further, a strong correlation (r = 0.65, P < Figure 2D ) in CRC cell lines, indicative of the major role of transcriptional mechanisms in the regulation of VEGF expression [23] . A similar correlation was observed in hypoxia between VEGF protein (by EIA) and VEGF mRNA expression ( Figure 3A) . Severe hypoxia induced different levels of VEGF expression up-regulation depending on the CRC cellular origin. Surprisingly, the fold change normoxia-hypoxia in VEGF expression of metastatic CRC cell lines was ≤ 1.5 in the majority of time points tested, as compared with the > 1.5-4.0 fold change in primary cell lines for both protein and mRNA VEGF ( Figure 3A) .
VEGF isoforms have differential angiogenic and tumorigenic activities and their expression pattern may also define the CRC cell angiogenic capacity [24] . Primary and metastatic CRC cell lines had a similar expression pattern of the three major isoforms VEGF121, VEGF169 and VEGF185, despite variability in VEGF expression ( Figure 3B ), implying a similar mechanism of regulation. VEGF121 was the predominant isoform expressed by CRC cell lines (58.23% ± 5.05% of total VEGF mRNA), as compared toVEGF165 and VEGF189 (15.13% ± 2.71% and 26.6% ± 6.5% of VEGF transcripts, respectively). In line with a previous study on tumor tissue [25] , the expression of the three isoforms was significantly associated with total VEGF protein; r = 0.55, P < 0.05 for VEGF121 and furthermore, VEGF165 and VEGF189 showed higher correlation (r = 0.67 and r = 0.69, P < 0.01, respectively) ( Table 3) .
VEGFR expression in colorectal cancer cell lines
While the role of the VEGF/VEGFR pathway in endothelial cells is well characterized, its functionality and expression by tumor cells is still controversial [13] . Soluble VEGFR-1 was quantified in CRC cell line supernatants at a lower range than VEGF (mean 8.3 and 27.8 pg/mL respectively) and no differences were found according to the cellular origin (7.57 ± 2.12 and 10.67 ± 3.1, in primary and metastatic CRC cell lines, respectively) ( Figure 4A ). In agreement with other studies [26] , a trend was observed for an inverse correlation between sVEGFR-1 and VEGF expression (data not shown), indicative of the angiogenesis inhibiting role of sVEGFR-1 [13] . In our CRC cell lines panel, the antibody array data showed a lack of expression of sVEGFR-2 ( Figure 1A) . Given the hypothesis that earlier tumor stages are more dependent on the VEGF/VEGFR signaling pathway [15] , we analyzed surface VEGFR-2 expression in CRC cells of primary origin. Flow cytometry revealed a general lack of surface VEGFR-2 expression in CRC cells of medium to high VEGF expression, as compared to HUVEC cell line ( Figure 4B ). These findings add to the stock of controversial results to date [27, 28] .
DISCUSSION
Identifying the proteins responsible for the different behavior of more advanced CRC tumors seems warranted in order to more effectively use current treatment options. Furthermore, there is a need to characterize definite biomarkers of CRC metastasis to serve as prognostic indicators and novel interventional targets. As derived from our findings in vitro, the tumor microenvironment of CRC metastases would be different to that of primary tumors, because of the effect of the CRC cells secreted factors. Metastatic CRC cell lines are characterized by a greater expression of cytokines majorly involved in metastasis, migration and invasion, while being proven proangiogenic effectors. MMP-1 plays an important role in CRC tumor invasion and metastasis [29] and MMP-9 has proved to be of prognostic value in stage Ⅱ colon cancer patients, where tumors with higher protein expression had a higher recurrence rate [30] . The monocyte attractant chemokine I-309 has been shown to stimulate chemotaxis and invasion of endothelial cells and the roles of IL-1α in colon cancer angiogenesis and of IL-2 in inflammation and apoptosis, seem also consistent with the metastatic phenotype [18, 31, 32] . Hypoxia is widely recognized as the major transcription effector for VEGF expression [9] . However, the greater (two-fold increase) induction of VEGF expression in hypoxia observed in primary CRC as compared to metastatic cell lines is an interesting finding which agrees with recent hypotheses. Tolerance to hypoxia is frequently acquired by tumor cells progressing towards more advanced phenotypes [15] . Our finding suggests the metastatic CRC molecular phenotype provides some intrinsic resistance to the hypoxic induction of VEGF expression. Some authors have shown that hypoxia would select more malignant metastatic cells, less sensitive to anti-angiogenic treatment [33] , to yield poorer patients outcomes [34, 35] . The community still agrees that angiogenesis is a hallmark of cancer in metastatic stages [36] . However, given the broad angiogenic network in the tumor microenvironment, research should move in the direction of investigating the mechanisms by which metastatic tumors depend on VEGF, since they seem to be different to those exploited by primary tumors [15] . Furthermore, with the objective of individualized care in mCRC, the distinct metastatic "sec- Further to the VEGF expression profile, the pattern of VEGF isoforms represents the next step to identifying intrinsic differences to guide treatment choice. However, the similar expression of VEGF isoforms across cell lines does not offer clarification. Further to this finding, it would be of interest to explore how VEGF transcription factors modulate the ratio of VEGF isoforms as disease progresses, given the changes on VEGF dependence. Interestingly, a novel class of VEGF isoforms, VEGFxxxb, generated through alternative splicing of exon 8, has been recently described [37] . Studies suggest anti-angiogenic or weak angiogenic properties for these isoforms [38, 39] . Not exempt from controversy, this discovery will help in further defining the role of VEGF/VEGFR signaling in CRC, yet still the testing techniques need refinement in specificity between the two classes.
Emerging data suggest VEGF to be a growth factor also for tumor cells and VEGF/VEGFR signaling to regulate their expression. However, this hypothesis remains unproven until consolidated results on VEGF receptor expression on tumor cells become available [12, 28] . Extensive work has been done on the activity of VEGF/VEGFR-1 signaling in CRC cells showing that it mediates cell motility and invasiveness but not cell proliferation [13] . While this would involve VEGF/VEGFR-1 in CRC progression and metastatic processes, sVEGFR-1 secretion was not found of significant relevance in metastasis-derived CRC cells. In contrast, not so much is known about the activity of VEGF/VEGFR-2 in cancer cells. Reports suggest an involvement in the sensitivity of CRC cells to inhibition of VEGF-related survival pathways [40] . However, controversial results on the VEGFR-2 expression on tumor cells to date [27, 28] , to which our results add, do not help to resolve this question. Definite confirmation of the expression and functionality of this pathway is necessary in order to shed more light on the mechanism of action of anti-VEGF therapies [40] . Consistent with the key role of VEGF in the "angiogenic switch" and the hypoxia-resistance mechanisms in metastatic stages, CRC cell dependence on VEGF in more advanced settings seems attenuated in favor of other cytokines in the progression of metastasis. Further investigation of these findings and testing the significance of the distinct "secretome" of CRC metastases at the clinic side seems warranted given the implications for patient outcomes.
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COMMENTS
Background
Identifying the proteins responsible for the different behavior of more advanced colorectal cancer is necessary in order to more effectively use current treatment options. The progressive growth of colon cancer depends on the blood vessels (angiogenesis) network within the tumor. Therapies targeting angiogenesis have emerged in the field; however, variances in the magnitude benefit lead to great amount of research to explain inter-individual differences. It is thought that different proteins or biomarkers in the tumor microenvironment are responsible for these facts.
Research frontiers
The lack in understanding of biomarkers of colorectal cancer metastasis led the authors to set up this work. Using a novel cytokine antibody array technique, this work identifies the differences in angiogenesis-related protein expression of colorectal cancer cell lines of primary and metastatic origin. This is the first step prior to translation into a clinic setting, where these differences are to be corroborated in patients with colorectal cancer.
Innovations and breakthroughs
The distinct profile of metastatic cell lines comprises eight proteins with different cellular properties, including favoring the growth of those tumor blood vessels. Interestingly, the classical angiogenesis marker vascular endothelial growth factor is not in such a profile, indicating that tumors in more advanced phases tend to rely on different mechanisms for their growth.
Applications
The findings of this work show that a number of markers might be of value when determining the course of disease in colorectal cancer. Furthermore, these proteins arise as novel intervention targets in the metastatic colorectal cancer setting.
